Biography
Dr. Charles B. Simone II is a radiation oncologist and one of the leading experts in proton beam therapy for mesothelioma. He has published extensively on intensity-modulated proton therapy (IMPT) as a way to deliver higher radiation doses to mesothelioma tumors while minimizing damage to the heart, lungs, and other nearby organs. Dr. Simone's research is advancing the role of proton therapy in the multimodal treatment of mesothelioma.
Education & Training
- Medical Degree — Drexel University College of Medicine (Medicine)
- Residency — Hospital of the University of Pennsylvania (Radiation Oncology)
Specialties & Procedures
Clinical Specialties
- Radiation Oncology
- Proton Therapy
- Thoracic Radiation
As a medical oncologist, Dr. Charles B. Simone II focuses on non-surgical treatment modalities including chemotherapy, immunotherapy, targeted therapy, and clinical trials.
Board Certifications
- American Board of Radiology — Radiation Oncology
Research Focus
Proton beam therapy for mesothelioma, intensity-modulated proton therapy (IMPT) for pleural malignancies, and radiation dose escalation with reduced toxicity.
Notable Publications
- Proton beam therapy for malignant pleural mesothelioma. International Journal of Radiation Oncology, Biology, Physics, 2019.
Legal Resources for Mesothelioma Patients
Patients diagnosed with mesothelioma after asbestos exposure may be eligible for compensation through asbestos trust funds and legal claims. Over $30 billion remains available in trust funds nationwide.
Frequently Asked Questions
What is proton therapy for mesothelioma?
Proton therapy uses proton beams instead of X-rays to deliver radiation. Protons stop at a precise depth, reducing radiation exposure to the heart and opposite lung. Dr. Simone has shown this can allow higher doses to mesothelioma while reducing side effects.
Is proton therapy available for all mesothelioma patients?
Proton therapy is available at select centers with proton beam facilities. Not all patients are candidates — it is typically considered for patients receiving radiation as part of a multimodal treatment plan after surgical evaluation.